Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1865 1
1910 1
1927 1
1932 1
1941 1
1942 2
1945 1
1946 1
1947 1
1950 1
1954 1
1955 1
1959 1
1960 1
1963 1
1964 1
1965 3
1966 7
1967 2
1968 5
1969 5
1970 5
1971 1
1972 2
1973 2
1974 4
1975 10
1976 9
1977 16
1978 14
1979 18
1980 15
1981 8
1982 16
1983 11
1984 14
1985 23
1986 17
1987 15
1988 21
1989 29
1990 24
1991 25
1992 30
1993 34
1994 26
1995 32
1996 28
1997 28
1998 30
1999 41
2000 41
2001 30
2002 37
2003 30
2004 44
2005 42
2006 37
2007 57
2008 55
2009 67
2010 66
2011 67
2012 62
2013 91
2014 99
2015 97
2016 104
2017 103
2018 113
2019 113
2020 115
2021 138
2022 137
2023 123
2024 68

Text availability

Article attribute

Article type

Publication date

Search Results

2,308 results

Results by year

Filters applied: . Clear all
Page 1
Machine Learning in Medicine.
Rajkomar A, Dean J, Kohane I. Rajkomar A, et al. Among authors: dean j. N Engl J Med. 2019 Apr 4;380(14):1347-1358. doi: 10.1056/NEJMra1814259. N Engl J Med. 2019. PMID: 30943338 Review. No abstract available.
Evidence-Based Practice: A New Dissemination Guide.
Dean J, Gallagher-Ford L, Connor L. Dean J, et al. Worldviews Evid Based Nurs. 2021 Feb;18(1):4-7. doi: 10.1111/wvn.12489. Epub 2021 Feb 3. Worldviews Evid Based Nurs. 2021. PMID: 33534186 No abstract available.
Acute flaccid myelitis: cause, diagnosis, and management.
Murphy OC, Messacar K, Benson L, Bove R, Carpenter JL, Crawford T, Dean J, DeBiasi R, Desai J, Elrick MJ, Farias-Moeller R, Gombolay GY, Greenberg B, Harmelink M, Hong S, Hopkins SE, Oleszek J, Otten C, Sadowsky CL, Schreiner TL, Thakur KT, Van Haren K, Carballo CM, Chong PF, Fall A, Gowda VK, Helfferich J, Kira R, Lim M, Lopez EL, Wells EM, Yeh EA, Pardo CA; AFM working group. Murphy OC, et al. Among authors: dean j. Lancet. 2021 Jan 23;397(10271):334-346. doi: 10.1016/S0140-6736(20)32723-9. Epub 2020 Dec 23. Lancet. 2021. PMID: 33357469 Free PMC article. Review.
Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study.
Kuppermann N, Holmes JF, Dayan PS, Hoyle JD Jr, Atabaki SM, Holubkov R, Nadel FM, Monroe D, Stanley RM, Borgialli DA, Badawy MK, Schunk JE, Quayle KS, Mahajan P, Lichenstein R, Lillis KA, Tunik MG, Jacobs ES, Callahan JM, Gorelick MH, Glass TF, Lee LK, Bachman MC, Cooper A, Powell EC, Gerardi MJ, Melville KA, Muizelaar JP, Wisner DH, Zuspan SJ, Dean JM, Wootton-Gorges SL; Pediatric Emergency Care Applied Research Network (PECARN). Kuppermann N, et al. Among authors: dean jm. Lancet. 2009 Oct 3;374(9696):1160-70. doi: 10.1016/S0140-6736(09)61558-0. Epub 2009 Sep 14. Lancet. 2009. PMID: 19758692
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Tam CS, et al. Among authors: dean jp. Blood. 2022 Jun 2;139(22):3278-3289. doi: 10.1182/blood.2021014488. Blood. 2022. PMID: 35196370 Free PMC article.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Wierda WG, et al. Among authors: dean jp. J Clin Oncol. 2021 Dec 1;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 7. J Clin Oncol. 2021. PMID: 34618601 Free PMC article. Clinical Trial.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Munir T, et al. Among authors: dean jp. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Am J Hematol. 2019. PMID: 31512258 Free PMC article. Clinical Trial.
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. Moreno C, et al. Among authors: dean jp. Haematologica. 2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012. Haematologica. 2022. PMID: 35021599 Free PMC article. Clinical Trial.
2,308 results